Eculizumab in kidney diseases
The C5 inhibitor monoclonal antibody, eculizumab, has been approved for the treatment of atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH); however, the efficacy and safety of this drug in treating other complement-related renal diseases has not yet been elucida...
Saved in:
| Main Authors: | , |
|---|---|
| 格式: | 图书 |
| 出版: |
Society of Diabetic Nephropathy Prevention,
2024-01-01T00:00:00Z.
|
| 主题: | |
| 在线阅读: | Connect to this object online. |
| 标签: |
添加标签
没有标签, 成为第一个标记此记录!
|
因特网
Connect to this object online.3rd Floor Main Library
| 索引号: |
A1234.567 |
|---|---|
| 复印件 1 | 可用 |